These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34731760)

  • 1. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
    Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
    Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
    Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors.
    Qiao XP; Wang XT; Wang S; Mu HX; Wang QS; Chen SW
    Bioorg Med Chem; 2024 May; 106():117752. PubMed ID: 38749341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
    Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
    J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
    Damaneh MS; Hu JP; Huan XJ; Song SS; Tian CQ; Chen DQ; Meng T; Chen YL; Shen JK; Xiong B; Miao ZH; Wang YQ
    Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Soga K; Honjo T; Takai S; Kawano Y; Kikuchi M; Nishidate A; Matsumoto F; Murase M; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129849. PubMed ID: 38876177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.